SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
If you or someone you know has a condition called chronic spontaneous urticaria (CSU), you may have heard about Xolair. In 2014, Xolair became the first medicine to be approved for treating this ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted, under ...
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed ...
Xolair is a brand-name prescription medication known as a biologic. Its active ingredient is omalizumab. Generic versions of biologic drugs are called biosimilars. Due to complex manufacturing ...
Xolair (omalizumab) is a prescription drug that works by blocking IgE to help reduce inflammation. Your response to this drug may vary based on your medical history and diagnosis. IgE is a protein ...
A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. Data ...
Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. In this trial, we assessed whether omalizumab, a ...
Purpose: The pharmacology, efficacy, dosage, adverse events, and economics of omalizumab are discussed. Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the Cε3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results